Drug intelligence / Profile preview

ORIL-019

Development stage: Preclinical
Lead developer: Oncology Research International
Modality: Small Molecules

Overview

**ORIL-019** is a preclinical, next-generation saponin-derived anticancer drug candidate being developed by Oncology Research International. Based on the company pipeline, it is designed to act at the cellular plasma membrane via a confidential specific molecular target, with a proposed mechanism involving membrane modification that can trigger apoptosis in cancer cells. ORIL-019 is being explored broadly in oncology across five unspecified cancer types, and the program is also described as having potential utility in immuno-oncology and as a vaccine adjuvant.

Beyond the preview

Go deeper on ORIL-019.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORIL-019.

Explore the full profile